Spss 11.5.0 for windows

Data from The Cancer Genome Atlas Research Network (TCGA; Lung AC and Lung Squamous Cell Carcinoma Provisional sequenced tumours sample sets) were used to analyse ADSL and ATIC genetic alterations including mRNA expression z-scores (Microarray, threshold 2.0) by use of CBIPORTAL software (http://www.cbioportal.org/, accessed on 29 June 2021). Exploration from Human genetic Atlas datasets and two public metabolomics databases from the study of Luo et al. [33 (link)] and from the study of Qi et al. [34 (link)] were conducted. The effect of ADSL and ATIC genetic expression on LC patient prognoses was evaluated by Kaplan–Meier survival curves of NSCLC patients with low or high mRNA expression (KMPLOTTER; http://www.kmplot.com/analysis, accessed on 19 June 2021). A log-rank test was calculated to determine differences in overall survival using SPSS 11.5.0 for Windows (IBM Corp., Armonk, NY, USA). For selecting the oncotargets with a significant survival rate, p ≤ 0.05 was set as a cut off parameter.

To analyze ADSL and ATIC genetic alterations including mRNA expression z‐scores (Microarray, threshold 2.0), data from The Cancer Genome Atlas Research Network (TCGA; Lung AC and Lung Squamous Cell Carcinoma Provisional sequenced tumors sample sets) were analyzed using cbioportal software ( http://www.cbioportal.org/) and visualized using the standard Oncoprint output showing altered columns. The effect of ADSL and ATIC genetic expression on LC patient prognoses was evaluated by Kaplan–Meier survival curves of LC patients with low or high expression of ADSL and ATIC with data from Kaplan–Meier plotter (kmplotter;http://www.kmplot.com/analysis). Data were collected using all available patients restricted to histological subtype for 120 months. Kaplan–Meier plots were constructed using graphpad prism version 6.0c (GraphPad Software, La Jolla, CA, USA), and a log‐rank test was calculated to determine differences in overall survival according to ADSL and ATIC mRNA levels using spss 11.5.0 for Windows (IBM Corp., Armonk, NY, USA).

We performed meta-analysis for breast cancer AE-survival, MR-free survival, breast cancer subtype, and breast cancers with clinicopathological information on 36 breast cancer datasets using bc-GenExMiner v3.1 (the website is: http://bcgenex.centregauducheau.fr/BC-GEM/GEM_Requete.php?mode=1) [16 (link)]. The analytical tools available for prognostic gene expression analysis in bc-GenExMiner were used to generate Figure 1 and 2 and Table 1, which include (1) Targeted analysis with N and ER subtyping; (2) Exhaustive analysis with N and ER subtyping; and (3) Analysis by molecular subtype. The difference in FAM83D mRNA expression levels between different statuses of FAM83D genomic alteration and TP53 mutation was analyzed by Mann-Whitney U. Kaplan-Meier plots were constructed and a log-rank test was used to determine differences among overall survival according to FAM83D mRNA levels in different cancer types. Spearman correlation was used to assess the association of FAM83D mRNA levels with CNA and mutation frequencies. All analyses were performed by SPSS 11.5.0 for Windows. A two-tailed p-value of less than 0.05 was considered to indicate statistical significance.